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1 Foreword 
In accordance with Prime Minister Juha Sipilä's Government Programme, the Govern-
ment is carrying out an implementation programme for rational pharmacotherapy. The 
programme is aimed, for example, at enhancing implementation of holistic treatment, 
improving people's functional capacity and creating the preconditions for cost-effective 
pharmacotherapy from the point of view of both patients and society (Prime Minister's 
Office 2015). 
The implementation programme for rational pharmacotherapy and its objectives by 
2022 are described in the final report of the programme (Ministry of Social Affairs and 
Health 2018). The reports of the working groups involved in the drafting of the imple-
mentation programme for rational pharmacotherapy are published at the same time. 
Each one of them focuses on a different theme and provides more in-depth infor-
mation about it. 
This research strategy has been drawn up as part of the implementation programme 
for rational pharmacotherapy. Background documentation includes the Ministry of So-
cial Affairs and Health's ‘Medicines Policy 2020’, which defines the national objectives 
for the pharmaceutical sector by 2020 (Ministry of Social Affairs and Health 2011).  
The document emphasises the role of the pharmaceutical services as part of the 
healthcare and social services system, and the customer-centred approach in the ac-
tivities of the pharmaceutical services. The research strategy takes also account of 
the government programme key project for improved home care for older persons and 
enhanced informal care in all age groups (Ministry of Social Affairs and Health 
2018b). Strengthening overall assessment of medical care is also a part of this key 
project. 
Pharmacotherapy is a central treatment method in various conditions. With a view to 
successful treatment outcomes, it is important to aim for rational pharmacotherapy 
that is effective, safe, economical, equal and of high quality (Ministry of Social Affairs 
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and Health 2018a). However, pharmacotherapy is not always rational. Pharmacother-
apy and its management need to be developed to ensure successful treatment out-
comes and functional implementation processes for pharmaceutical treatment. 
Pharmacotherapy and its implementation must be based on research and good clini-
cal practice. Research is needed on the efficacy and effectiveness of pharmacother-
apy and the practical management of pharmacotherapy. Research focusing on ra-
tional pharmacotherapy allows us to identify areas for development in the pharma-
cotherapy processes and improve the safety of pharmacotherapy. With the help of re-
search, we can also monitor the impacts of administrative decisions, care recommen-
dations and other measures, as well as the use of resources. Cooperation between 
various stakeholders and well-functioning monitoring systems are required to produce 
high-quality research data and to develop relevant activities. 
The objectives of this research strategy are 1) to identify and describe research areas 
for the implementation of rational pharmacotherapy, 2) to find methods to promote uti-
lisation of research data in the management of rational pharmacotherapy, 3) to in-
crease research cooperation and enhance preconditions of research and 4) to identify 
needs for new research initiatives and methodological development. 
The research strategy supports the realisation and monitoring of the implementation 
programme for rational pharmacotherapy by targeting research to such areas of re-
search that are essential from the perspective of rational pharmacotherapy. The ob-
jective is to produce scientific advice that serves the implementation of rational phar-
macotherapy in practical patient work as well as in the planning of health and social 
services at national, organisational and regional levels. The research strategy is in-
tended as a support document for researchers, research groups, research organisa-
tions, and health and social services organisations in their planning work. It is also 
hoped that the strategy would serve the needs of research funding providers in the 
targeting of research funding. 
1.1 How Was the Research Strategy 
developed? 
The preparation of the research strategy was performed by the working group on re-
search for the implementation programme for rational pharmacotherapy (Appendix 1). 
The strategy draws on the draft document drawn up earlier by the Finnish Medicines 
Agency Fimea in 2015 and the statements received on it. When compiling the strat-
egy, account was taken of the existing research information, and the new research 
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needs and methodological development needs that came up in connection with draw-
ing up the implementation programme for rational pharmacotherapy. 
To map out the existing research data, in spring 2017 the working group conducted a 
review of research related to rational pharmacotherapy in Finland. The group sent an 
open invitation to researchers and research networks for wide distribution via the Min-
istry of Social Affairs and Health, urging people to pass it on. The invitation was also 
published on the Fimea website. In the invitation, researchers and research groups 
were asked to briefly describe their own research projects related to rational pharma-
cotherapy and the most important research publications made on them. At the same 
time, researchers were asked to report if they were interested in joining the research 
network of rational pharmacotherapy to be established. 
In the various stages of working on the research strategy, the group took account of 
the feedback received from the steering group of the implementation programme for 
rational pharmacotherapy. Furthermore, the draft strategy underwent a public consul-
tation round in autumn 2017. 
1.2 Current State of Rational Pharmacotherapy 
Research 
1.2.1 What are the Research Topics? 
Based on the review and other information gathered by the working group on research 
for the implementation programme for rational pharmacotherapy, the research data 
available is focused on the following areas: 
• Most of the research done on the use of medicines has focused on the 
use of medicines among the elderly, as well as the inappropriateness, 
problems and risks of pharmacotherapy, using pharmacoepidemiology 
research methods and registers. In recent years, studies searching 
ways to identify, manage and prevent problems caused by pharma-
cotherapy have become more common. The methods used have in-
cluded research on the impacts of multidisciplinary cooperation and the 
assessments of medical care, the development of identification tools for 
medication risks, and enhancement of the medication competence of 
healthcare and social services personnel as well as improvement of the 
basic, continuing and specialist training to this end. 
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• Pharmacoepidemiology research has produced basic information on the 
trends in the use of medicines, and results of such research have been 
published annually in the Finnish Statistics on Medicines (Finnish Medi-
cines Agency Fimea and Kela 2016). Other studies have compared the 
use of medicines in accordance with such variables as gender, age, 
hospital district and the degree of specialisation of the attending physi-
cian. The research has increasingly shifted to combining information on 
the use of medicines with data gathered from other registers, which al-
lows the use of epidemiological methods for recognising factors associ-
ated with the use of medicines, and identifying health benefits and risks 
caused by medicines. In recent years, research has included such top-
ics as the pros and cons of statins, the impacts of exposure to medi-
cines during pregnancy, the effects of pharmacotherapy on the develop-
ment of memory disorders and the state of health of those suffering from 
memory disorders, and the connection between medication and cancer 
morbidity. 
 
• Pharmacokinetic research for the promotion of pharmaceutical safety is 
focused on studying drug interactions and their mechanisms, and more 
recently, the impact of genetic factors on the drug response and taking it 
into account when planning individual pharmacotherapy. 
 
• Research related to pharmaceutical safety has studied such subjects as 
the implementation of the EU Pharmacovigilance Directive, which came 
into effect in 2012.  An area of particular research interest has been how 
medication users themselves participate in reporting adverse drug reac-
tions, on one hand, in EU countries with a long tradition of user partici-
pation, and, on the other hand, in countries where user participation be-
gan with the entry into force of the directive. 
 
• The quality and accessibility of medicines information, and medicines in-
formation practices have been studied in different operating environ-
ments. Most of the studies have focused on the councelling practices in 
pharmacies. In addition, quite a few studies have been made on the 
sources and need of medicines information among the general popula-
tion and healthcare professionals, and the medicines education of chil-
dren. The focus of research is shifting to empowerment, literacy in medi-
cines information, and the impressions people have of conditions and 
their drug treatment as factors affecting their medication-taking behav-
iour. In addition, researchers have tried to find methods for studying the 
effectiveness of medicines information. Research on medicines infor-
mation and its application has been enhanced as part of Fimea's Medi-
cines Information Strategy with the help of the Medicines Information 
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Network (Finnish Medicines Agency 2012, Järvinen et al. 2013, Medi-
cines Information Network 2016, Mononen et al. 2018). 
 
• System-based medication safety research was launched in Finland as 
part of the national patient safety work (Ministry of Social Affairs and 
Health's Steering Group for the Promotion of Patient Safety 2006–2009, 
Turvallinen lääkehoito guidelines on safe pharmacotherapy 2006, Na-
tional Institute for Health and Welfare’s patient safety programme Poti-
lasturvallisuutta taidolla 2011–2014). Based on the research review con-
ducted in 2015, a total of 18 peer-reviewed Finnish medication safety re-
search papers have been published (Hakoinen et al. 2017). Several 
studies in different operating environments are currently under way, es-
tablishing various lines of research. Furthermore, several theses and dif-
ferent research and development reports have been made on the sub-
ject. The increased use of medication incident reporting systems in the 
health and social services organisations has stimulated research as 
well. A lot of medication incidents related to distribution, administration 
and documenting of medications have been reported. Therefore, organi-
sations have begun to develop new operating practices for these func-
tions using such tools as updated patient-specific medication lists and 
electronic dispensing systems. However, there is very little reported data 
available on medication incidents related to prescribing drugs and the 
need of drug therapy from all operating environments. Both in Finland 
and internationally, the focus in the medication safety research is shift-
ing towards supporting proactive medication safety work and safety cul-
ture by means of, for example, identifying high-risk medications and situ-
ations in different operating environments and specialities, and, based 
on them, drawing up safeguards and making the implementation pro-
cesses of pharmacotherapy safer (WHO 2017). 
 
• The impacts of medicines policy decisions have been studied from vari-
ous perspectives, such as generic substitution from the viewpoints of so-
ciety, medication users, physicians and pharmaceutical supply chains. 
Assessments have been made on the impacts of the introduction of 
electronic prescription system on the prescribing and supply of medi-
cines, and medication safety. Research has also been conducted on the 
impacts of the changes in the medication reimbursement system, the in-
troduction of biological medicines and the relevant decision-making, and 
the availability of medicines. The legislative amendment that led to ex-
tending the sale of nicotine replacement products from pharmacies to 
other outlets has been assessed as a political process. 
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• Intervention studies for examining the effectiveness of rational pharma-
cotherapy in different operating environments have become more com-
mon. The purpose of such research is to produce new information with a 
view to developing new operating practices. Research has been carried 
out on such issues as the effectiveness of pharmaceutical services, mul-
tidisciplinary assessments of pharmacotherapy, safety checks and auto-
mated drug dispensing systems. Furthermore, intervention studies have 
been conducted to investigate what would be functional means for, for 
example, reducing long-term use of sleeping pills and antipsychotics 
among the elderly. In the field of comparative effectiveness research, 
hospital districts and their units – hospital pharmacies, for example – 
have taken the initiative and produced information for the development 
of their own activities and decision-making processes. 
 
Some register-based observational studies have also been conducted 
on the effectiveness of pharmacotherapy, which is becoming more com-
mon due to the development of register data and research methodology. 
 
• Pharmacoeconomic research is quite a new field of study in Finland and 
it is seeking a position as part of the comparative effectiveness research 
on healthcare. Pharmacoeconomics applies the methods of health eco-
nomics for studying phenomena related to pharmacotherapy. Over the 
past few decades, the competence in pharmacoeconomic research 
methods and their introduction to use has increased, and a few educa-
tional and research units with their own lines of research have been es-
tablished. 
 
In Finland, pharmacoeconomic research has been carried out on, for ex-
ample, the impact of pharmacotherapy on the patient's and his or her 
family member's quality of life when treating memory disorders, and the 
cost-effectiveness of biological medicines and traditional rheumatoid ar-
thritis medications when treating rheumatic diseases. In addition to ac-
tual pharmacoeconomic research, the methods of evidence synthesis 
and economic assessment are applied, for example, by authorities. Ex-
amples of this are submission files and the health economic evaluations  
required for the decisions on the reimbursement status and wholesale 
price of medicinal products made by the Pharmaceuticals Pricing Board 
produced and Fimea's assessment of the therapeutic and economic 
value of medicines. Systematic literature reviews have become more 
common in scientific research particularly as part of theses. 
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1.2.2 Where Is Research Conducted? 
The rationality of pharmacotherapy is studied at universities, particularly in the fields 
of medicine, pharmacy and nursing science, sector research institutes, hospital dis-
tricts and universities of applied sciences providing education in healthcare. 
Research supporting rational pharmacotherapy is also included among the statutory 
duties of various authorities. For example, the Social Insurance Institution of Finland 
(Kela) carries out research serving the development needs of the benefits systems 
and Kela's own activities on a statutory basis (Act on Social Insurance Institution 
731/17 August 2001), which in case of reimbursements for medicines means research 
related to the reimbursement system for medicine expenses and use of medicines. 
Furthermore, the register data collected by Kela and the methodological competence 
related to their use at Kela Research are important for other parties conducting regis-
ter-based research. Kela also finances research on rehabilitation, prevention of ill-
nesses and health insurance pursuant to the Act on the rehabilitation benefits and re-
habilitation allowance provided by the Social Insurance Institution (566/15 July 2005). 
It has played an important role in the financing of research promoting rational pharma-
cotherapy. 
In addition to its duties as a licensing and supervisory authority, Fimea has been as-
signed specific research and development duties, including the implementation of 
pharmacoepidemiology and pharmacoeconomic research and research related to 
medicines policy (Act on the Finnish Medicines Agency 593/24 July 2009). Further-
more, Fimea is tasked with building cooperation within the fields of research men-
tioned above. 
The statutory duties of the National Institute for Health and Welfare include the re-
search, monitoring and promotion of the health and welfare of Finnish people and the 
reduction of relevant problems, as well as conducting research and development ac-
tivities within the sector for the promotion of national health and welfare (Act on the 
National Institute for Health and Welfare 668/31 October 2008). 
Research is also conducted in hospital districts, hospitals and other health and social 
services organisations, pharmacies, hospital pharmacies and the pharmaceutical in-
dustry. State Research Funding (VTR, formerly Special State Subsidy, EVO funding), 
based on the amount of scientific publications, has been an important source of fund-
ing for rational pharmacotherapy research and development in the healthcare sector. 
Most of this funding has been used for medical research and education, but also for 
R&D projects in, for example, nursing sciences and pharmacy. Multidisciplinary re-
search projects through, for example, specialist training have become more common 
in recent years. 
REPORTS AND MEMORANDUMS OF THE MINISTRY OF SOCIAL AFFAIRS AND HEALTH  25/2018 
 
15 
 
 
 
The pharmaceutical industry produces a lot of research data throughout the life cycle 
of a medicinal product. Some of this is issued as scientific publications, and some of it 
becomes public in connection with the marketing authorisation process and pharma-
covigilance. However, major part of the research data is internal business information 
that is never published. Even after the marketing authorisation has been granted, the 
pharmaceutical company needs to supplement the research data related to a medici-
nal product. This research data is used, for example, for health economic evaluations 
that are attached to the application for the reimbursement status application. Re-
search data may also accumulate in connection with adaptive pathways and condi-
tional licensing procedures, fulfilment of the obligation to provide information poten-
tially related to conditional reimbursement decisions or in connection with pharma-
covigilance. In addition, companies may need to monitor the targeting of the use of a 
medicinal product and treatment in large patient populations and to identify patient 
groups who benefit the most from the treatment. 
1.2.3 Current State of Research: Strengths and Oppor-
tunities, Weaknesses and Threats 
The assessment of the current state of research on rational pharmacotherapy is 
shown in table 1. Versatile and multidisciplinary research in rational pharmacotherapy 
of high scientific standard is being conducted in Finland. It is utilised in both decision-
making on medicines policy and in practical promotion of rational pharmacotherapy. 
In the future, the new data produced by the health and social services information 
systems will offer new opportunities if it can be effectively harnessed for research use. 
Enhanced collaboration between research groups and participation of health and so-
cial services regions in the production of research data and its application are also im-
portant future opportunities. Increasing interdisciplinary and multidisciplinary research 
cooperation enables the study of rational pharmacotherapy from novel perspectives. 
Particularly, the observation of the theories and methodologies of social and behav-
ioural sciences in research supporting rational pharmacotherapy is an important op-
portunity that could be used for strengthening understanding of the patient's perspec-
tive as well as the operating models. 
As weaknesses, we can consider scarce research funding and lack of other re-
sources. There is also room for development in the targeting of research to areas that 
are essential from the perspective of rational pharmacotherapy. Not much research 
has been conducted from the patient's perspective, even though the need for such re-
search is substantial. It can be considered a threat that research promoting rational 
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pharmacotherapy will continue to be regarded as a marginal discipline, and no re-
sources can be found for conducting such research. In order for research infrastruc-
ture to function properly, it is required that resources are allocated for expert services 
to support researchers in, for example, information search, research methodology, 
statistics and data processing. 
Table 1 The current state of rational pharmacotherapy research: strengths and opportunities, weaknesses 
and threats 
STRENGTHS WEAKNESSES 
- Versatile and multidisciplinary rational 
pharmacotherapy research is conducted in many 
different places, where established research groups 
have emerged. 
- The research conducted is of high scientific 
standard. 
- Research is utilised for decision-making on 
medicines policy, for example when drafting 
legislation. 
- Research is used for promoting practical work, for 
example when developing operating models, tools 
and information systems. 
 
- There is very little long-term research. 
- Research groups are small and operate in isolation 
from each other. The number of senior-level 
researchers is small. 
- Funding and other resources are scarce. Research 
infrastructure is insufficient. 
- There is room for improvement in the research 
methodology competence. 
- Cooperation with researchers, health and 
medicines policymakers and health and social 
sector actors is unbalanced. 
→ room for improvement in the application of 
academic research information in particular. 
- From the perspective of rational pharmacotherapy, 
the focusing of research is unbalanced. For 
example, relatively few studies have been 
conducted on initiating medication, whereas the 
number of studies on the use of medicines is much 
higher. The number of studies conducted from the 
patient's perspective is small. 
OPPORTUNITIES THREATS 
 
- The new information produced by health and social 
services information systems and biobanks that can 
be utilised for research purposes. 
- Enhancing cooperation between research groups 
→ joint funding, multidisciplinary research groups 
and research data of higher quality. 
- Research will become part of the duties included in 
the health and social services system, and the 
health and social services regions will participate in 
the production and utilisation of research 
information. 
- Interdisciplinary and multidisciplinary research and 
new research initiatives.  
- Promotion of the quality of pharmacotherapy and 
medication safety by means of, for example, 
promotion of evidence-based pharmacotherapy and 
drug treatment practices. 
 
- Research projects remain undone or they are 
discontinued due to scarce resources or 
fragmentation. 
- Research competence weakens. 
- From the viewpoint of science policy, 
pharmacotherapy is a marginal field of research. 
- Insufficient communication of the meaning of 
rational pharmacotherapy research to funding 
providers and users of research data. 
- Research is dropped out of the duties of the health 
and social services system. 
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- Finding ways for curb the rise in medication 
expenditure and increasingly precise targeting of 
pharmacotherapy. 
- Development of social, technological and service 
innovations that support the implementation of 
pharmacotherapy. 
- Utilising artificial intelligence in support of clinical 
decision-making and generation of academic 
research materials, with the data recorded in patient 
records and biobanks serving as the basis. 
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2 Vision and Goals of Research 
 
Research data is used for promoting rational pharmacotherapy and safe pharma-
cotherapy practices. The motto is: Promoting effective use of research information in 
the implementation of rational pharmacotherapy. 
By the year 2022 
• the research and development related to rational pharmacotherapy has 
been integrated into the operations of the health and social services sys-
tem, 
• research results are utilised diversely in steering the activities in the 
health and social services system and in making decisions on medicines 
policy and 
• research and allocation of resources to the key research areas pre-
sented in the research strategy are strong. 
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3 Key Research Areas and Themes 
The key research areas and themes with a view to implementation of rational pharma-
cotherapy have been collected into figure 1, which serves as the foundation of the re-
search strategy. The research areas summarised in the figure correspond with Dona-
bedian's (1997) principles of the factors affecting the quality of care. Some of them 
are related to structures and operational preconditions, some to implementation pro-
cesses of care, and others to the impacts and effectiveness of care. 
When applying the Donabedian model to rational pharmacotherapy, the key research 
areas and themes are: 1) the structures and operational preconditions supporting ra-
tional pharmacotherapy, 2) implementation processes of pharmacotherapy promoting 
medication safety and 3) the effectiveness of pharmacotherapy (figure 1). 
These three main research areas can be divided into more exact research themes 
and detailed objectives, which are based on the definition of rational pharmacotherapy 
(WHO 1987, Ministry of Social Affairs and Health 2018a) (figure 1). 
Therefore, by means of research we seek to promote the development of structures 
and processes, and to monitor the impacts and effectiveness of pharmacotherapy, 
taking into account the goals of rational pharmacotherapy. 
REPORTS AND MEMORANDUMS OF THE MINISTRY OF SOCIAL AFFAIRS AND HEALTH  25/2018 
 
20 
 
 
Figure 1 A model illustrating the implementation of rational pharmacotherapy, present-
ing the identified key research areas and themes in relation to the goals of rational 
pharmacotherapy. The research strategy is built in accordance with the figure.  
The research themes presented in figure 1 are described in more detail in the follow-
ing chapters. The descriptions take into account the research needs that came up 
during the preparation of the implementation programme for rational pharmacotherapy 
in relation to the existing research data and the research methods used. The descrip-
tion of each research theme is followed by a list of research topics. The lists are not 
all-inclusive, but they suggest important research areas and needs for targeting re-
search from the viewpoint of the implementation programme for rational pharma-
cotherapy. 
3.1 Research Related to Structures and 
Operational Preconditions 
The themes of research related to structures and operational preconditions can be di-
vided into four parts: 1) the pharmaceutical service system, 2) medication compe-
tence of health and social care professionals, as well as 3) information systems and 
4) medicines information, which can be used to support the implementation of rational 
pharmacotherapy in various healthcare and social services settings (Figure 1). 
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3.1.1 Pharmaceutical Services in Various Healthcare 
and Social Services Settings 
According to the existing research data, the management of pharmacotherapy as a 
whole is one of the biggest challenges of the rational pharmacotherapy. The ongoing 
health and social services reform allows examination of the structures of pharmaceuti-
cal services and mobility of data between, for example, various operating units and or-
ganisations. With the help of well-functioning structures, it would be possible to en-
sure that pharmaceutical services provides optimal support for the implementation 
and overall management of pharmacotherapy in various health and social services 
operating units in the public and private sectors as well as in the third sector. 
It is important that the continuation and monitoring of necessary drug treatment is im-
plemented in a seamless manner when a patient/client moves from one unit or profes-
sional to another in accordance with his or her individual treatment pathway. That re-
quires patient/client-specific treatment pathways and well-coordinated practices that 
should extend to use and monitoring of drug treatment. From the pharmaceutical ser-
vices this requires not only efficient pharmaceutical logistics but also solutions pro-
moting the therapeutic quality of pharmacotherapy and medication safety, and clinical 
pharmacy services. 
As the health and social services system and drug therapies develop further, the inter-
face between inpatient and outpatient care is expected to dissipate. The digitalisation 
of the health and social services system is aimed towards the same goal. For medica-
tion users and patient care team members digital services enable a new kind of partic-
ipation in the implementation and monitoring of the impacts of pharmacotherapy. The 
potential freedom of choice will change for its part the way people behave when using 
health and social services and pharmaceutical supply services, which will become vis-
ible in the implementation of pharmacotherapy. This will increase the pressure to 
change the present multisource financing system of pharmaceutical services. 
The planned changes in the health and social services described above need to be 
supported by research, where pharmaceutical service is examined as part of the 
health and social services system from a totally new perspective and as a provider of 
new kind of pharmaceutical supply services for health and social services. The study 
should assess the tasks, cooperation, operational preconditions and cost-effective-
ness of the current public pharmaceutical supply services (the existing hospital phar-
macies and pharmaceutical centres of hospital districts) and the pharmaceutical sup-
ply services of private outpatient care (outpatient pharmacies) as part of the health 
and social services system. At the same time, it should be examined how the pharma-
ceutical services of other health and social service providers has been arranged, how 
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it functions and how it could be integrated into/coordinated with other pharmaceutical 
supply services. 
Documentation that could be used as a starting point for research include the policies 
presented in the Ministry of Social Affairs and Health’s ‘Medicines Policy 2020’ and 
the policies drawn up by the various working groups involved, where the duties of 
pharmaceutical service in the health and social services structures is studied in closer 
detail (Voipio-Pulkki et al. 2013, Ministry of Social Affairs and Health 2015). The latest 
policies for the development of the pharmacy system were drawn up by the working 
group to develop pharmacy operations set up by the Government in 2017 (The policy 
lines of the working group of government parties to develop pharmacy operations 
2017). New research data and the earlier research data collected systematically is 
needed as background information for the implementation of decisions, for monitoring 
the impacts and cost-effectiveness of changes, and for reacting to changes, if neces-
sary. 
Research Topics 
• The development of the tasks, structures and services of pharmaceutical 
service to respond to the needs of the health and social services system 
and citizens in the implementation of rational pharmacotherapy. 
• The coordination of pharmaceutical service in inpatient and outpatient 
care. 
• The expansion of pharmaceutical service from efficient pharmaceutical 
logistics to solutions promoting the therapeutic quality of pharmacother-
apy and medication safety, and to clinical pharmacy services. 
• The funding, effectiveness and cost-effectiveness of pharmaceutical ser-
vice. 
• The functionality of pharmaceutical service and supply of medicines un-
der normal conditions and in crisis situations. 
3.1.2 Medication Competence of Healthcare and Social 
Services Professionals as a Basis of Rational 
Pharmacotherapy 
The medication competence of healthcare and social services professionals lays the 
foundation for rational pharmacotherapy and medication safety. The medication com-
petence provided during basic training includes the readiness to provide counselling 
to medication users and self-care guidance, to monitor drug treatment and to collabo-
rate multiprofessionally. With the help of research, it is possible to examine the medi-
cation competence of various healthcare and social services professionals and the 
sufficiency of training in the development of such skills. In addition, research should 
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be targeted to finding new methods for developing medication competence at work-
places by, for example, enhancing self-study and interprofessional learning with the 
help of digitalisation and web-based learning. More research data is also needed on 
how practical use of this knowledge could be promoted. For example, the WHO has 
drawn up an extensive training programme in multiprofessional patient safety that also 
includes a medication safety aspect (WHO 2011 and 2017). 
Research Topics 
• The medication competence of various healthcare and social services 
professionals in relation to work tasks and drug treatment responsibili-
ties. 
• The development needs of training related to content of teaching and 
teaching methods. 
• The opportunities provided by digitalisation in the basic and continuing 
training, workplace-specific training and self-study related to rational 
pharmacotherapy. 
• Learning organisations from the viewpoint of the implementation of ra-
tional pharmacotherapy (participatory action research). 
• The need of coordination in pharmacotherapy training and the methods 
for implementing coordination. 
• The impact of interprofessional training on medication competence, 
medication safety, patient welfare and satisfaction, patient's quality of 
life and care expenditure. 
3.1.3 Information Systems in the Implementation of Ra-
tional Pharmacotherapy 
Healthcare information systems, such as client and patient information systems, are 
important tools for healthcare professionals and medication users in the implementa-
tion of rational pharmacotherapy. The activity of citizens in the management of per-
sonal welfare, self-care and treatment adherence can also be promoted by means of 
improving the management and flow of information, and by increasing the provision of 
electronic services and remote connections. Malfunctioning information systems, on 
the other hand, endanger patient and medication safety and may lead to serious ad-
verse events. Therefore, the usefulness and effectiveness of these new data manage-
ment and care applications in the pharmacotherapy should be studied more than is 
currently done. They constitute one subject of health technology assessment, the im-
portance of which will increase significantly in the provision of health and social ser-
vices. 
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The health and social services system is currently undergoing extensive information 
system and data management reforms. One of the most important reforms that have 
already been implemented is the introduction of an electronic prescription system. It 
has changed, for example, the way data is stored, as well as the opportunities of both 
healthcare professionals and patients to examine the medication prescribed and re-
newal of prescriptions. It is also still important to study how the electronic prescription 
systems works so that its properties could be developed further from the perspectives 
of both healthcare professionals and medication users. One such research subject is 
the electronic renewal of prescriptions and its impact on rational pharmacotherapy. 
Electronic prescriptions are part of the National Archive for Health Information 
(Kanta), where healthcare units record patient data from their own information sys-
tems in a data secure way. This information is available to all healthcare units. In the 
My Kanta online service, patients have access to their own patient records, including 
all care and medication data. In the future, they can also personally enter data on their 
own state of health and care into My Kanta. The goal is that, in the future, Finland 
would have a uniform national medication list in shared use. All parties participating in 
patient care and, using My Kanta, the patient himself or herself could view the medi-
cation list in the same format. To bring these new data management systems to opti-
mal use, research data is needed on such issues as how citizens learn to use the sys-
tem and actively record their health information as part of self-care. On the other 
hand, it is important to use research for identifying population groups with no opportu-
nities to use electronic patient information systems and other services supporting 
pharmacotherapy. 
Different risk management tools (e.g. drug interaction databases and databases on 
drugs suitable for the older persons) and decision-making support systems have been 
developed and adopted both in Finland and abroad to provide support for physicians 
in their prescribing activities and for the risk assessment of pharmacotherapy. At best, 
decision-making support systems combine the patient's health information collected 
from electronic patient records to medical data, and produce operating and care in-
structions tailored for the patient in question. These databases are widely available in 
Finland throughout the health and social services system and pharmaceutical service. 
However, the integration and use of databases does not yet happen in an optimal 
fashion in the existing patient information systems. Research data would be needed 
on, for example, how people are able or capable of using the databases in care work, 
how their use can be promoted, and what their effectiveness is like. 
The development of healthcare information systems is part of the national ‘Health and 
Social Services Data to Effective Use’ strategy (Ministry of Social Affairs and Health, 
and Association of Finnish Local and Regional Authorities 2014). The Kanta services 
and new health applications open new opportunities for not only developing care but 
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also for research on the effectiveness of pharmacotherapy and medication safety. 
Storage of data in structured format is important with a view to the usability of docu-
mented data, patient care and research use. 
Research Topics 
• The digitalisation of health and social services and the accessibility, usa-
bility, utilisation and effectiveness of information systems in the promo-
tion of rational pharmacotherapy in health and social services, taking ac-
count of the needs of the users and the operating environment about to 
change as a result of the health and social services reform. 
• Remote connections, as well as self-care and self-management services 
increasing the activity of citizens in the maintenance of their own wellbe-
ing, and their effectiveness and usability in the promotion of rational 
pharmacotherapy in healthcare. 
• The usability and effectiveness of the health information personally rec-
orded by patients. 
• The use of patient information system data as research material for 
studies on the patients’ medication use, treatment adherence and the 
effectiveness of pharmacotherapy. 
• The usability of artificial intelligence in the processing of clinical, elec-
tronic patient record data as a tool for decision-making and monitoring of 
care, and as a research tool. 
3.1.4 Medicines Information as Precondition of Rational 
Pharmacotherapy 
Easily accessible evidence-based medicines information provided in a suitable format 
is one of the structural preconditions of rational pharmacotherapy and medication 
safety (Ministry of Social Affairs and Health 2011, Finnish Medicines Agency Fimea 
2012). Medicines information helps medication users acquire sufficient competence 
and coping skills needed for successful pharmacotherapy. This requires high literacy 
in health and medicines information, the achievement of which should be supported in 
schools, for example. 
Consumers and medication users have access to increasing amounts of different 
sources of information, which they can use independently to search for the infor-
mation they need on illnesses and their treatment. Even though active support has 
been provided for independent search of medicines information, particularly physi-
cians and pharmacists still have a strong position as sources of medicines infor-
mation. 
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With a view to supporting successful pharmacotherapy outcomes for patients, it is es-
sential that healthcare and pharmaceutical service professionals have access to relia-
ble information sources and services that they are capable of using. Professionals 
also need good communication skills and clinical interview skills for customer-oriented 
counselling. The medication counselling provided by various professionals should be 
harmonious and mutually complementary, and it should be based on national recom-
mendations and local agreements. The preconditions for this are provided by shared 
diseases and medication databases widely available within healthcare and pharma-
ceutical service, as well as medicines information services. The importance and effec-
tiveness of these databases and services for the promotion of rational pharmacother-
apy should be studied more than is currently done. This research data could also be 
used for the planning of the accessibility and quality of medicines information and 
medicines information services in the health and social services reform. 
One important part of medicines information consists of the medicines information 
produced by the pharmaceutical industry for marketing purposes. Very few studies 
have been conducted on it either in Finland or internationally. Research data would be 
needed on the effects of pharmaceutical marketing on the formation of the impres-
sions of health and medicines, and the increase in the need for drug treatment (medi-
calisation). The rapid increase in the number and versatility of marketing channels in 
social media in particular increases the need for research. 
The medicines information network and its research group have drawn up an updated 
strategy on research policies for medicines information until 2020 (Medicines Infor-
mation Network 2016). 
Research Topics 
• Access to and literacy in medicines information among general popula-
tion. 
• The quality, availability, accessibility and usability of medicines infor-
mation in health and social services and pharmaceutical service. 
• The risk management tools of pharmacotherapy from the perspective of 
medicines information. 
• The information needs and sources related to the medicines among 
healthcare and pharmaceutical service professionals and general popu-
lation/medication users, the search strategies for medicines information 
and the use of such information. 
• The use of electronic data sources and enabling their use, novel meth-
ods of communication. 
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• The need of and access to medicines information in special groups, 
such as people with memory disorders, the mentally disabled, sign lan-
guage users, the visually impaired and immigrants, and the usability of 
the existing medicines information in different patient groups. 
• The implementation of national recommendations for medication coun-
selling in the new health and social services structures to support suc-
cessful pharmacotherapy outcomes of patients, from the perspective of 
patients in particular. 
• The effectiveness of medicines information and medicines information 
services. 
• Pharmaceutical marketing as a factor affecting prescribing and use of 
drugs. 
• The methods and information contents of pharmaceutical marketing. 
3.2 Research Related to Promotion of 
Medication Safety 
The implementation of pharmacotherapy is part of rational pharmacotherapy and a 
factor with decisive influence on treatment outcomes (WHO 2017). In this research 
strategy, the implementation of pharmacotherapy is examined as a patient-oriented 
process in different healthcare and social services settings. 
The implementation of pharmacotherapy includes the following main stages, with var-
ying areas of focus in accordance with the setting: 1) initiating medication, 2) dispens-
ing of medicines, 3) provision of pharmacotherapy, 4) user perspective, 5) monitoring 
and assessment of pharmacotherapy, 6) duration, discontinuation and termination of 
pharmacotherapy and 7) proactive risk management and safeguards in the pharma-
cotherapy process (Figure 1). 
3.2.1 Initiating Medication 
There are various sub-processes associated with initiating medication, such as mak-
ing the diagnosis, selecting the treatment suited for the person in question, assess-
ment of the need for medication, prescribing drugs (writing the prescription), explain-
ing the drug therapy to the medication user or his or her representative to the extent 
deemed necessary at the time the drug is prescribed, and agreeing on the follow-up 
of drug therapy with the medication user and other parties participating in the provi-
sion of drug therapy (e.g. Routasalo et al. 2009, Kekäle 2016). 
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The following factors have an effect on how the initial stage of the use of medication 
proceeds: is the patient starting a new medication, does the present medication con-
tinue or is a drug regimen replaced with another one. Many other factors, such as the 
patient's medical conditions, treatment motivation, state of health, life situation and 
the ability to take responsibility for personal drug treatment, also affect initiation of 
medication. Furthermore, the circumstances around initiating medication and the op-
erating environment play an important role. Factors affecting how successfully drug 
treatment begins include diagnostics and the establishment of the need for medica-
tion, the time reserved for going through the matters related to the medication during 
appointment, the tools available, information sources and systems, and documenta-
tion of medication decisions. 
Plenty of international research has been done on the prescribing practices of drugs 
and the factors affecting prescribing decisions. On the other hand, less research has 
been conducted on the importance of the initial stage of medication from the perspec-
tive of patient safety, which the WHO has just recently urged us to pay more attention 
to (WHO 2017). In a systematic literature review that examined factors causing seri-
ous medical errors in primary healthcare, the making of diagnosis and writing the rele-
vant prescriptions as well as insufficient monitoring of pharmacotherapy arose as is-
sues endangering patient safety (Panesar et al. 2016). 
In Finland, very few studies have been conducted on the prescribing practices of phy-
sicians and nurses with limited prescribing rights, and factors affecting prescribing de-
cisions. The information gathered from Kela's prescription archives gives an overall 
impression of the prevailing trends in prescribing and use of drugs, but more research 
data is needed on the initiation and repeat prescribing of medication, and the factors 
affecting how the prescriber operates. 
Studying the initiation process of drug treatment is important also because the tools 
and databases assisting in the initiation process have developed and become more 
versatile, enabling planning of patient-specific medication. They also promote proac-
tive risk management in pharmacotherapy. The challenges posed by electronic tools 
and processes are their fragmentation, their laborious use, as well as how adept the 
prescribers are in using them when making medication decisions. Therefore, more re-
search data is needed to develop these innovations further and put them into practice. 
On the other hand, information is needed on the impacts of electronic databases and 
decision-making support system as well as electronic prescriptions and the Kanta ser-
vices on prescribing of drugs and rational pharmacotherapy. 
The amended Decree on Prescriptions (1088/2010), which entered into force at the 
beginning of 2017, increased the prescriber's responsibility for ensuring the necessity 
of the drug treatment prescribed by him or her and taking account of its costs. At the 
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same time, the period of validity of prescriptions was extended from one year to two 
years, which is a major change in the implementation practices of pharmacotherapy. It 
increases the pressure to delegate the responsibility for the monitoring of pharma-
cotherapy from those who initiate it to other healthcare and pharmaceutical service 
professionals. This increases the need for closer multiprofessional collaboration 
across health and social services particularly as regards long-term drug therapies 
(see chapter 3.2.5 Monitoring and Assessment of Pharmacotherapy for more details). 
In addition to research on the prescribing process of medication, more research data 
is also needed on the prescribing and repeat prescribing processes regarding specific 
patient groups and certain medicines/medication groups. Such patient groups include 
the elderly and people with multiple conditions or other patients for whom it is more 
challenging than usual to plan an individual medication regimen and other patients 
with challenges in pharmacotherapy. The specific medication groups include antipsy-
chotics, analgesics and antimicrobial agents, high-risk medicines and expensive drug 
therapies, where treatment decisions must be made after careful cost-effectiveness 
considerations. 
The prescribing practices of nurses with limited prescribing rights should also be stud-
ied. It should also be studied how pharmacists participate in the initiation of medica-
tion and repeat prescribing and how this affects medication safety (e.g. they review 
the medicines the patient is using, update the medication list information, perform a 
medication ‘safety check’ and interview the customer on how well the drug therapy 
has succeeded). 
Research Topics 
• Research and understanding of the prescribing process: making the di-
agnosis and differential diagnosis, establishing the need for medication, 
making the decision on drug treatment and selecting the drug, taking 
into account the evidence-based pharmacotherapy and other individual 
factors affecting the choice. Deciding on the duration of drug treatment. 
• The usability of electronic databases and decision-making support sys-
tems intended to provide support for prescribers in their decision-mak-
ing, when planning patient-specific drug therapies, and the effectiveness 
of such tools for rational pharmacotherapy and curbing medication ex-
penditure. 
• The prescribing practices of antipsychotics and analgesics, as well as 
medicines classified as narcotics and how these can be affected. 
• Prescribing high-risk medicines. 
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• Pharmacotherapy and prescribing practices of vulnerable patient 
groups, such as children, pregnant women, the elderly, persons with 
multiple conditions, the disabled and people with rare diseases. 
• Prescribing expensive drug therapies and financial planning of pharma-
cotherapy in practice. 
• The impact of the patient's financial situation and the drug reimburse-
ment system on prescribing drugs. 
• Counselling and collaboration with the patient when initiating or continu-
ing the medication. 
• Multiprofessional collaboration and flow of information in various phases 
of pharmacotherapy, particularly when initiating medication, deciding on 
the continuation of medication, in repeat prescribing and in problem situ-
ations. 
• Studying the social factors affecting how the prescriber operates from 
the viewpoints of the rationality and expenses of pharmacotherapy (e.g. 
pharmaceutical marketing, social media, health and medicines policy 
decisions). 
• The impact of prescribing practices on the medicalisation and iatrogene-
sis. 
• Monitoring of the impacts of the updated Decree on Prescriptions. 
• Relaunching the monitoring and research activities on rational use of an-
timicrobial agents launched with the MIKSTRA project at the turn of the 
century. 
• The implementation and quality of prescribing by nurses with the limited 
prescribing rights. 
• Understanding and observation of the organisation-based factors affect-
ing initiation and continuation of medication in the promotion of rational 
pharmacotherapy (e.g. use of medication incident reports, implementa-
tion research, safety culture research). 
3.2.2 Dispensing of Medicines 
1) Community Pharmacies 
The key task of community pharmacies is to dispense both prescription drugs and 
over-the-counter (OTC) medications to the persons in outpatient care who need medi-
cation. Today, the clients of such pharmacies increasingly use methods other than 
personal visits to take care of their business (e.g. doing business through an online 
pharmacy, an agent or home care). Regardless of the way business is done, when 
dispensing drugs, the pharmacy is obliged to ensure the safety of pharmacotherapy 
and the correct use of medicines (Medicines Act 395/1987). 
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Administrative regulation for dispensing medicines assign minimum duties for pharma-
cies for checking that the prescription provides sufficient information on taking the 
drug, and on the duration and purpose of use of the drug treatment. At the pharmacy, 
this data must be transferred to the user in writing on an instructions label, and it must 
be communicated to the user when handing out the medicines or in some other way. 
In addition, many pharmacies routinely check, for example, drug interactions of im-
portance for treatment. 
The most researched area of the dispensing process at community pharmacies is 
medication counselling. The objective has been to study how well medication counsel-
ling is integrated into the normal medication dispensing process and thus ensure not 
only the fulfilment of the pharmacy's counselling obligation but also the quality of 
counselling from the customer's point of view by means of, for example, pseudo cus-
tomer studies. The reliability of delivery at pharmacies has been monitored on a regu-
lar basis. In addition, relatively numerous studies have been conducted on profes-
sional services supporting successful pharmacotherapy provided by pharmacies, the 
development needs of information management at pharmacies and the functionality of 
the electronic prescription system. 
In the future, the new health and social services system will constitute the new operat-
ing environment for community pharmacies, with and alongside which they will func-
tion. The policy laid down in the Ministry of Social Affairs and Health's medicines pol-
icy document and the supplementary working group memorandums (Ministry of Social 
Affairs and Health 2011, Voipio-Pulkki et al. 2013, Ministry of Social Affairs and Health 
2015) is that among the duties assigned to pharmacies increasing emphasis will be 
laid upon counselling on the use of medication, support for self-management and 
monitoring of pharmacotherapy, as well as financial planning of pharmacotherapy 
from the perspectives of the user and the payer. The duties of pharmacies as suppli-
ers of medicines and in ensuring the appropriateness and safety of pharmacotherapy 
implemented among population in outpatient care within their area of operation (Medi-
cation Act 395/1987) will probably be extended in the future. 
In the future, research should be targeted to studying how the dispensing of medi-
cines from a pharmacy combined with prescribing constitutes a safe and appropriate 
entity from the perspectives of the medication user, prescriber, pharmacy and the rest 
of the healthcare system (cf. Fimea administrative regulation 2/2016). It is important 
that the prescriber and the pharmacy locally agree on measures promoting medication 
safety and rational use of medication, and controlling the growth of medication ex-
penditure (e.g. assessment of the range of medicines from the perspectives of care 
recommendations and local needs, optimal use of information systems, agreeing on 
division of duties and responsibilities). Furthermore, it should be examined how the 
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stakeholders could agree on appropriate procedures for ensuring the quality of medic-
inal products and medication safety if the pharmacy is in charge of the supply of medi-
cines to health and social services units. 
The supply of medicines trough online pharmacy services was allowed in 2011 and it 
has brought new operating models using various service channels to outpatient sup-
ply of medicines. Their impacts on rational pharmacotherapy and the opportunities 
they provide for advancing it should be studied. Pharmacies have introduced elec-
tronic tools for medication counselling and risk management of pharmacotherapy 
(mostly the same ones that are in use also elsewhere in health and social services). 
More research is needed on their functionality, use and effectiveness in the promotion 
of rational pharmacotherapy and risk management of drug treatment. Extending the 
research on the reliability of delivery of medication to security of supply and the duties 
of pharmacies as part of Finland's security of supply work has emerged as a new area 
of research. Getting prepared for availability problems deriving from the operations of 
the pharmaceutical industry is part of this work. 
Research Topics 
• The duties and opportunities of pharmacies in the advancement of ra-
tional pharmacotherapy as part of the health and social services system. 
• Treatment practices related to self-care, drug treatment prescribed by a 
physician/dentist/nurse with limited prescribing rights and promotion of 
health, and their effectiveness. 
• The practices and effectiveness of medication counselling, support for 
self-management and monitoring of drug treatment in the promotion of 
rational pharmacotherapy. 
• Dispensing of medicines through automated dose-dispensing: the need 
to develop practices to promote medication safety and effectiveness. 
• Digitalisation of pharmacy operations and the effect of multichannel ser-
vices (e.g. a pharmacy's brick-and-mortar store and online service) on 
the implementation and advancement of rational pharmacotherapy. 
 
2) Hospital Pharmacies and Medicine Dispensaries 
The delivery of medicines from hospital pharmacies and medicine dispensaries to 
wards has changed significantly over the past decade. The changes have been 
caused by, for example, organizational changes in the pharmaceutical service of hos-
pitals and other health and social care units aimed at establishing bigger pharmaceuti-
cal service units, procuring drugs in larger batches, and more efficient pharmaceutical 
logistics. The use of automation has increased in the ordering of medicinal products to 
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wards and in their storage and reconstitution. With the closure of medicine dispensa-
ries, many care organisations have lost their own pharmaceutical staff. On the other 
hand, in many other places the job description of the staff has become increasingly 
clinical and the number of staff has increased significantly. 
The dispensing practices of medicinal products are still changing rapidly in Finland as 
new procurement and delivery systems are being introduced as part of the automation 
and digitalisation of healthcare. The new systems also promote medication safety, 
which is an important reason for adopting such systems. At the same time, part of the 
pharmaceutical staff transfers from logistics tasks to working in care teams to support 
the therapeutic quality of pharmacotherapy. In such change situations, it is important 
to conduct research by which processes of pharmacotherapy and the duties of the 
staff can be optimised, and the safety and effectiveness of new practices can be eval-
uated. 
Essential medicines list has an established position in the implementation of the phar-
maceutical service in hospitals and other facilities. The purpose of the essential medi-
cines list is to steer choices of medicines and to influence the rationality of pharma-
cotherapy, but they also make pharmaceutical logistics simpler and more efficient. 
However, very few studies have been conducted on the use of such essential medi-
cines. 
Research Topics 
• Optimising the ordering and dispensing practices at a regional level and 
in healthcare and social services organisations. 
• Study of the changes in the dispensing processes of medicinal products 
in hospitals and other institutional care units of health and social ser-
vices from the perspectives of medication safety and effectiveness. 
• Integration of pharmaceutical logistics and the ward services of clinical 
pharmacy. 
• The impacts of the basic selection of medicinal products at hospitals on 
the choice of medicines, pharmacotherapy and pharmaceutical logistics. 
• Dispensing practices of expensive medicinal products with a view to op-
timising expenditure. 
• The effects of new drug treatments and dosage forms on the dispensing 
practices and tailoring of drug therapies for different patients. 
• The security of supply and operation of the pharmaceutical services of 
hospitals and other care facilities in emergency conditions. 
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3.2.3 Provision of Pharmacotherapy 
As a rule, the provision of pharmacotherapy can be divided into inpatient or outpatient 
provision of drug therapy. In healthcare, inpatient care typically refers to care provided 
at hospitals, health centre hospitals and in residential homes for the elderly However, 
the division between inpatient or outpatient care is variable and sometimes also prob-
lematic because of the interface between private and public sectors. Increasingly de-
manding drug therapies are provided in outpatient care, such as at home, in assisted 
living facilities and in housing service units. Pharmacotherapy is also provided at 
many atypical places, such as schools, often without the presence of a healthcare 
professional. 
Provision of pharmacotherapy includes the entry of medicinal products used by the 
patient/client into the patient information systems, keeping the medication data up to 
date, dispensing and administering medicines to the patient or taking care that the pa-
tient takes the medication intended for him or her (Inkinen et al. 2015). If necessary, 
the pharmacotherapy process also includes reconstitution of medicinal products. 
Pharmacotherapy is provided in multiprofessional collaboration, where the areas of 
responsibility and tasks of each professional, and flow of information between the var-
ious actors, facilities and patients should be well defined and known by all parties in-
volved. The patient's medication data being up to date and the transfer of information 
play a key role in safe pharmacotherapy (WHO 2017). 
Deviations in the documenting, dispensing and administration of medication are the 
most common medication errors recorded in the medication incident reporting sys-
tems, such as the HaiPro system. The reporting of medication incidents and learning 
from the reported data has been one of the stimuli for setting out to reform the prac-
tices of pharmacotherapy in places like hospital wards. Former “medicine cups” have 
been replaced by electronic medication therapy management systems. There is al-
ready plenty of experience of such systems in other countries, but it would be im-
portant to study their effectiveness and functionality in Finland as well. 
Medication therapies provided in hospitals differ significantly from outpatient drug 
therapies. Hospitals use a lot of intravenous drugs and solutions, antimicrobial agents, 
cancer drugs and analgesics the reconstitution, dosing and monitoring of which re-
quires demanding competence. On the other hand, the morbidities of hospitalised pa-
tients pose extra challenges for safe of pharmacotherapy. Therefore, pharmacother-
apy and its pharmacotherapy in hospitals should be studied more in Finland, using dif-
ferent research methods and, for example, data available in reporting systems. 
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In outpatient care, medication user himself or herself or his or her family members are 
mainly responsible for the provision of drug therapy. The pharmacists in pharmacies 
provide important support for this. They give advice and counselling on the use of 
medication when dispensing the prescription. Home care employees also often partic-
ipate in the provision of drug therapies to older people in outpatient care in particular. 
Earlier studies have shown that the development of the healthcare system and the 
support provided by it have not been able to keep up with the transfer of the provision 
of pharmacotherapy to outpatient care. Therefore, more research is needed on the 
methods for promoting medication safety and on medication incidents particularly in 
homes, outpatient care and atypical settings. 
Research Topics 
• Research on the provision of pharmacotherapy and pharmacotherapy 
processes in various settings. Research should take account of the or-
ganisational viewpoint, associated with better use of medication incident 
data both methodologically and in terms of content, for example, identifi-
cation of the contributing factors and root causes of the objects most 
susceptible to risk. Studying the safety, suitability and effectiveness of 
dispensing, administration, and documenting practices of medication 
and how medication is taken. 
• Pharmacotherapy in atypical facilities and settings. 
• Pharmacotherapy provided by home care. 
• Collaboration within care teams, between care teams/care facilities and 
with the medication users and their family members. 
• The impact of clinical pharmacy and clinical pharmacology services on 
the safe provision of pharmacotherapy and expenditure in different oper-
ating environments. 
• Reconstitution of medicinal products at wards and in hospital pharma-
cies (e.g. the impact of automation on practices). 
• Safety risks related to medicinal product packaging and product names. 
3.2.4 Management of medications 
In most drug therapies, the medication user personally acts as provider of pharma-
cotherapy. Therefore, medication users play a central and active role in the promotion 
of rational pharmacotherapy. The Finnish medicines policy also emphasises the pa-
tient's/client's own activity in the treatment of long-term conditions and symptoms that 
are easy to treat on one's own (Ministry of Social Affairs and Health 2011, Finnish 
Medicines Agency Fimea 2012). Still, there is very little information on pharmacother-
apy from the patient's/client's perspective, even though it would be essential to ensure 
that appropriate support and monitoring systems could be built for the process of 
pharmacotherapy, when reforming the health and social services system. At the same 
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time, it should be better acknowledged what a vast potential and resource medication 
users themselves are and how this potential could be utilised better with the help of 
empowerment and participation. 
In long-term medical conditions, the purpose of support for self-management and 
monitoring of drug therapy is to enhance the patient's adherence to treatment. The 
medication adherence is affected by several factors, such as factors related to the 
healthcare systems, care, the patient and his or her medical condition, as well as so-
cial and financial factors (e.g. WHO 2003). This is a major public health challenge, the 
root causes of which are still being sought, also internationally. A contributing reason 
to this are the research methods used, which have not provided an understanding 
perspective on the implementation process of pharmacotherapy and the factors af-
fecting it in people's everyday lives. 
Research on treatment adherence should give us a better understanding of the every-
day lives of medication users and the way they cope with their medication than we 
have today. We would need particularly qualitative research deriving from the per-
sonal experiential world of medication users, with the help of which we could better 
understand, for example, the way medicines are used and their impact on the treat-
ment outcomes reached, and medication users’ own thinking of how pharmacotherapy 
should be arranged. Therefore, research should be targeted to understanding the 
context-reliance of the use of medicines: how the patient uses the medicine within a 
specific period of time, in a specific place or in a specific setting, when surrounded by 
diverse information, beliefs and culture. Such understanding can be gained by multi-
disciplinary research, involving experts from such fields as social and behavioural sci-
ences. It is also important to include patients in the research teams, so that the re-
search questions and settings could be formed in a patient-oriented manner. 
Even though a large share of ailments is treated in self-care, there is very little re-
search data on self-care and rational use of self-care medication either in Finland or 
abroad. Therefore, research should be targeted to promotion of rational self-care and 
self-medication as part of the health and social services system. It should be esti-
mated by research to what extent the use of other health and social services can be 
optimised by enhancing rational self-care and self-medication, and how collaboration 
and division of labour between pharmacies and local health services could be coordi-
nated more efficiently. 
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Research Topics 
• The empowerment, participation and self-management in the pharma-
cotherapy of both short-term and long-term medical conditions. 
• The study and understanding of the empowerment process and its 
meaning for the effectiveness of pharmacotherapy. 
• Patient's expectations for and experiences of drug therapies as part of 
holistic treatment of medical conditions. 
• Partnerships in pharmacotherapy and support given for it, particularly to 
those who have multiple morbidities and use a lot of medication. 
• Observing people who use high-risk medication or are otherwise in need 
of special support in the implementation of drug treatment. 
• Supporting the drug treatment pathway from the patient's point of view: 
client care plan and medication list, guidance and counselling, follow-up 
of care, using peer support and its meaning. 
• The rapid development of health technologies and integrating them to 
new drug therapies under development (e.g. pharmacoeconomics). 
• The promotion of self-monitoring of the impacts of drug treatment by tra-
ditional means and with the help of health technologies (e.g. self-moni-
toring of blood pressure and blood glucose, INR and CRP measuring, 
use of My Kanta in self-management). 
• Diagnostics of self-managed ailments at home and in pharmacies, differ-
ential diagnostics. 
• Examining the root causes of good and poor treatment adherence. 
• Factors promoting medication adherence and their observation when 
developing the health and social services structures. 
• Implementation, effectiveness, and therapeutic and financial significance 
of self-medication. 
• Citizens’ satisfaction with the availability of self-care medication, infor-
mation available on self-care medication and attitudes towards the use 
of self-care medication. 
• The connection between the pharmacotherapy and the use of health 
and social services and the need of hospital care. 
• Inappropriate polypharmacy and investigating its root causes. 
• Potential harmful medicines in various age groups, high-risk medication 
and their connection to clinical adverse reactions and use of services. 
• Incorrect ways of using medicines. 
• Prescription drug abuse. 
• Medication use among special groups, such as immigrants. 
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3.2.5 Monitoring and Assessment of Pharmacotherapy 
The purpose of the monitoring of pharmacotherapy is to ensure the impacts and suc-
cess of treatment, evaluate the whole holistic pharmacotherapy process, and examine 
the patient's need for information and experiences of drug therapy. By monitoring 
pharmacotherapy, it is possible to improve treatment outcomes, specify the objectives 
of medication, identify potential adverse effects and support patient's treatment adher-
ence. The key tools for the monitoring of pharmacotherapy are the client care plan1 
and up-to-date medication list. It also requires functional collaboration with the medi-
cation user. 
The client care plan (cf. treatment plan) is a plan on the practical implementation of all 
health and social services the client may need based on his or her personal need of 
services (Draft Bill for the Freedom of Choice Act in Health and Social Services of 19 
October 2017). It also includes up-to-date information on the patient's medication, and 
the objectives and monitoring of drug therapy. Drawing up a client care plan and using 
it for supporting the patient's drug therapy and self-management has not yet become 
a general practice. Research data is needed to promote the use of the plan. 
It is one of the biggest obstacles to implementation of rational pharmacotherapy that 
the health and social care services lack up-to-date information on an individual pa-
tient's medication. Even though all prescriptions and information on medication pur-
chases are electronically stored in the Prescriptions Centre of Kanta services, so far, 
it is impossible to recognise from this data which of the medicines are in use at any 
given time, or to generate an up-to-date medication list. This calls for not only the de-
velopment of information systems but also a change in practices, so that physicians 
would systematically enter information about termination of medication or cancelled 
prescriptions to the Prescriptions Centre. On the other hand, the update of a medica-
tion list must always include a medication review to ensure that the drug treatment is 
appropriate for the patient. In this context, the concept of medication review includes 
assessment measures on different levels, of which the one that best serves the moni-
toring needs of the patient's drug treatment is implemented (medication review, medi-
cation assessment, comprehensive medication assessment). 
                                                
 
1 In accordance with the draft bill for the Freedom of Choice Act in Health and Social Services of 
19 October 2017 client care plan refers to a plan concerning examinations, treatment or medical 
rehabilitation in accordance with section 4 of the Act on the Status and Rights of Patients 
(785/1992), a service and care plan in accordance with section 7 of the Act on the Status and 
Rights of Social Services Clients (812/2000), a client care plan in accordance with section 39 § of 
the Social Services Act, a service plan in accordance with section 16 of the Social and Health 
Services for Older Persons, a service plan in accordance with section 3a(2) of the Act on Services 
and Assistance for the Disabled (380/1987) and a client plan in accordance with section 30 of the 
Child Welfare Act (417/2007). 
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The medication review may be performed by a physician or it may be performed multi-
professionally between pharmacists and nursing professionals.  Based on the review, 
the physician decides on potential changes in the care plan. The objective is to en-
hance medication safety and the quality of pharmacotherapy. There is not much infor-
mation available on the cost-effectiveness of medication reviews (Kiiski et al. 2016). 
Research data is needed particularly on how medication reviews could be targeted to 
the persons who would benefit from them the most. The implementation and perma-
nence of changes in medication also affect the cost-effectiveness of the reviews. Fur-
thermore, information is needed on the functionality and benefits of multiprofessional 
collaboration in the monitoring and optimisation of pharmacotherapy. 
Research Topics 
• Implementation of the monitoring of pharmacotherapy and the holistic 
pharmacotherapy process: taking the medicine, measuring of the state 
of health, therapeutic and adverse effects, problems in drug therapy, 
high-risk medication. 
• The use of a client care plan and overall management of medication for 
people with long-term or multiple medical conditions or polypharmacy or 
otherwise undergoing demanding drug treatment. 
• The appropriateness of pharmacotherapy, the medication information 
being up to date and the transfer of data from one care unit to another or 
to home care (including information on the use of over-the-counter 
(OTC) medicines and nutritional supplements). 
• The usability and coverage of the national medicines list included in the 
Kanta services after its introduction. 
• The impacts of the national medicines list on the success rate of phar-
macotherapy and the resources assigned to implementation of pharma-
cotherapy in health and social services and the pharmaceutical service. 
• Cost-effective screening and identification of persons with therapeuti-
cally significant medication problems or risks in different operating envi-
ronments. The development of criteria for identifying problems and risks 
in pharmacotherapy. 
• The development, targeting and implementation of multiprofessional as-
sessment practices for pharmacotherapy in different health and social 
services operating units. 
• The development of the process for ensuring that the patients who have 
problems in their medication or monitoring of their drug therapy can be 
identified, their problems solved, changes in their medication imple-
mented and their medication monitored and reviewed on a regular basis. 
• Monitoring medication errors and learning from them, examining the root 
causes. 
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• The implementation and effectiveness of clinical pharmacy services in, 
for example, informal care, assisted living facilities, supported housing 
units, and atypical settings for providing drug therapy, such as schools. 
• Methodological development of comparative effectiveness research on 
the monitoring and assessment of pharmacotherapy. 
 
3.2.6 Duration, Discontinuation and Termination of 
Pharmacotherapy 
The intended duration of pharmacotherapy should be decided already when planning 
drug treatment. The objective and duration of treatment should be entered in the med-
ical records and the client care plan. The necessity of medication should be checked 
periodically. Research has revealed that the medications intended for short-term use 
often remain in long-term use. On the other hand, regimens intended as long-term 
treatment are often discontinued, even though they would still benefit the patient. Suf-
ficient duration of pharmacotherapy should be ensured by means of the monitoring of 
medication outcomes and use, and by making sure that the patient is aware of the ob-
jectives of drug therapy. At the same time, the real and potential adverse reactions 
caused by drug therapy should also be considered, especially when the treatment 
continues for an unnecessarily long period of time. 
There is only quite limited amount of research data and evidence-based guidelines 
available on making changes in pharmacotherapy – discontinuing medication in par-
ticular – both in Finland and abroad. However, discontinuation of medication has be-
come a subject of active research. Even though the details of the discontinuation pro-
cesses of many drug therapies remain unexplored, we know that various drug regi-
mens need to be tapered according to a specific plan. To ensure that the discontinua-
tion process succeeds, it is important that it is realised in collaboration between pa-
tients and the persons responsible for their care. Information systems also need to be 
developed, so that they would provide improved support for the monitoring of the du-
ration of pharmacotherapies and discontinuing them, if necessary. Therefore, even 
when using the existing information systems, one should remember to make entries 
on the duration of drug therapy and terminating/discontinuing the use of medication, 
and to cancel prescriptions as needed if there are no longer grounds for continuing 
the use of medication. 
Research is needed on the frequency of inappropriate duration of medication and its 
causes. Furthermore, it should be studied in what kind of drug therapies and patient 
groups inappropriate duration of medication is most typically detected. This would 
help in focusing the attention to the key problem areas. The research data could also 
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be used for developing the competence that healthcare and social services profes-
sionals need when discontinuing pharmacotherapy. Provision of such competence 
should be included as part of their basic studies, and sufficient continuing training on 
the subject should also be ensured. 
Research Topics 
• The frequency of inappropriate duration of medication and its causes. 
• In what kind of drug therapies and patient groups inappropriate duration 
of drug treatment is most typically detected. 
• Discontinuing medications and making other revisions in medication (es-
pecially antipsychotics, antidepressants, hypnotics and other benzodiaz-
epines, proton-pump inhibitors, bisphosphonates). 
• Extended use of medication intended for short-term treatment. 
• Renewal of prescriptions and continuation of medication. 
• Insufficient duration of long-term medication. 
• The competence needed for discontinuing and terminating drug thera-
pies and the development of such competence. 
• Collaboration with the patient in the planning, monitoring and discontinu-
ation of medication. 
3.2.7 Proactive Risk Management and Safeguards in 
the Pharmacotherapy Process 
Medication safety work is shifting from the retrospective research of medication errors 
and incidents towards proactive risk management, pharmacovigilance (WHO 2017). 
Retroactive information is also needed on medication incidents and factors contrib-
uting to them, allowing the identification of areas of risk in processes of pharmacother-
apy. Based on this data, it is possible to change the provision processes of pharma-
cotherapy and build safeguards by which the generation of risks can be prevented. 
The safeguards can include such measures as checking the weight of a child patient 
and writing it down on the prescription, medication counselling, use of a medication 
lists, review and safety checks of medication, and risk management and decision-sup-
port applications incorporated into information systems. In the future, it should also be 
possible to use research for screening the most effective and cost-effective safe-
guards. 
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Research Topics 
• Retrospective and prospective identification of medication risks in vari-
ous patient groups and operating environments. 
• Development, testing and further development of safeguards. 
• Safeguards as innovations. 
• The effectiveness and cost-effectiveness of safeguards. 
• Developing methods for research on proactive management of medica-
tion risks. 
3.3 Research on the Use of Medicines and on 
the Effectiveness of Pharmacotherapy 
The research on the use of medicines and on the effectiveness of pharmacotherapy 
can be divided into the following sub-areas: 1) research on the use of medicines, 2) 
medication safety research, 3) research on the effectiveness and cost-effectiveness of 
medicinal products and pharmacotherapy, and 4) research on the cost of medicinal 
products and pharmacotherapy (figure 1). 
3.3.1 Use of Medicines 
Basic research on the use of medicines has been conducted in Finland for a long 
time. In addition to register-based studies, the research methods have included exten-
sive population studies and interviews, and qualitative research. The register-based 
studies in particular have made extensive use of the data from the Prescription Regis-
try of the Social Insurance Institution (Kela). 
The research on the use of medicines using both descriptive and evaluating methods 
produces basic information about prescribing and dispensing of medicines, consump-
tion of medicines, actual use of medicines and direct costs of medicines. With the help 
of the research on the use of medicines, we can also gather information about medi-
cation adherence, continuation of drug treatment, and inappropriate medication or tar-
geting of medication in the population. Research on the overall picture of the use of 
medicines is needed to analyse the constantly rising pharmaceutical expenditure and 
inappropriate use of medicines, and for finding solutions to these problems. On the 
other hand, the development of treatments and processes also benefits from the re-
search on the use of medicines. 
The use of medicines changes over time and it has many societal, medical and finan-
cial consequences. It is affected by, for example, the development of medicine and 
REPORTS AND MEMORANDUMS OF THE MINISTRY OF SOCIAL AFFAIRS AND HEALTH  25/2018 
 
43 
 
 
methods of treatment, care guidelines, morbidity among the population, the range of 
medication on the market, the drug reimbursement system, the individual prescription 
practices of physicians and pharmaceutical marketing. The use of medicines varies 
regionally not only between countries but also within countries. Long, statistical time 
series play a central role in research. The objective is to promote safe and efficient 
use of medicinal products by identifying factors leading to appropriate and inappropri-
ate use of medication, and by making research efforts to find methods by which the 
use of medicines can be steered in a more appropriate direction. Making comparisons 
in the use of medicines between different regions or countries, and predicting 
changes in use patterns and affecting them helps in the process. 
The existing data resources, merging data collected from various registers and com-
bining register data to information gathered using surveys and interviews enable more 
versatile study of the rational use of medication than is currently possible with the help 
of population-based materials. In addition to register-based studies, different patient 
and population studies and qualitative studies provide valuable information on the use 
of medicinal products and the factors affecting it at the individual and systemic levels. 
The qualitative research in particular should be increased and methodologically diver-
sified by utilising new methods available for gathering real-world information about 
people's experiences of the use of medicinal products. For example, social media en-
ables the analysis of the use of medicines from materials covering large research 
populations. 
Research Topics 
• The trends in the use of medicines in different public health problems 
and other conditions and in vulnerable patient groups, such as the el-
derly, pregnant women, persons with multiple medical conditions, the 
disabled and people with rare diseases. 
• Acquisition of the prescribed medicines from a pharmacy. 
• Factors affecting the use of medicinal products. 
• Description of the treatment using real-world data, care pathway analy-
sis. 
• Inappropriate pharmacotherapy and problems in drug treatment, factors 
creating incorrect ways of using medication. 
• Qualitative research of the use of medicinal products and ways of using 
medicines (description of the phenomenon and understanding it, re-
search applying the theory and research creating theoretical models). 
• The development of research methods for studying the use of medicinal 
products. 
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3.3.2 Drug Safety 
An area of medication research that has become internationally important is drug 
safety and pharmacovigilance, the starting points of which are risk management of 
pharmacotherapy and promotion of patient safety. The WHO has defined pharma-
covigilance as a field of science and activities aimed at identifying, assessing, under-
standing and preventing adverse reactions of medicinal products and other problems 
caused by medication (WHO 2002). 
Pharmacovigilance and related research related to it is conducted by the pharmaceu-
tical industry, the authorities as well as universities, and all of the above in collabora-
tion with each other. Pharmacovigilance and 
research are internationally established operations (within EU coordinated by EMA, 
with the WHO Collaborating Centre for International Drug Monitoring based in Upp-
sala serving as global coordinator). 
Traditionally, drug safety research has utilised risk signals data concerning various 
medication user groups that physicians and other healthcare professionals have re-
ported to authorities. In recent years, the participation of medication users in sponta-
neous reporting of adverse drug reactions has become more common. However, re-
search has increasingly expanded to using register-based research methods and 
other real-world data, allowing the study of impacts of medicinal products on large 
population groups (Kaeding et al. 2017, Santoro et al. 2017). The research focuses 
on, for example, conditions caused by medication, currently including such topics as 
heart risks caused by anti-inflammatory drugs, dementia/cognitive adverse effects 
caused by medication, the metabolic effects of medication – on the onset of diabetes 
in particular (e.g. statins and antipsychotics) – and the effects of long-term use of pro-
ton-pump inhibitors. 
In Finland, not much drug safety research has been conducted in spite of excellent 
opportunities for such study. The book published by Kaeding and his research team in 
2017 gives a fresh analysis of pharmacovigilance in the European Union (Kaeding et 
al. 2017). The analysis compares practices in six member states (Germany, Portugal, 
Finland, the United Kingdom, Poland and France). 
Research Topics 
• Research of the monitoring data on adverse drug reactions in Finland 
and other countries. 
• Development of research methods for adverse drug reactions. 
• Conditions caused by medication. 
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• Adverse drug reactions experienced by medication users. 
• The adverse effects of new medicinal products (e.g. biological medi-
cines) and their management. 
• The common and rare adverse drug reactions caused by extensively 
used medication, such as medications for diabetes, high cholesterol, 
high blood pressure and asthma, analgesics and antipsychotics, and 
complementing their adverse effects profiles. 
 
3.3.3 Effectiveness of Pharmacotherapy 
Research on the effectiveness of pharmacotherapy refers to the examination of the 
capacity of drug therapy to generate the intended effects under real-world circum-
stances, in people’s normal lives, and as part of the everyday health and social ser-
vices. The effectiveness can be studied, for example, by means of observational re-
search, pragmatic design of trials, register-based design of trials or other intervention 
study methods. Unlike in randomised clinical trials, in comparative effectiveness re-
search dropping out of a trial, poor treatment adherence or change of trial groups do 
not lead to exclusion of the study, and the inclusion criteria applied are quite permis-
sive (Choudhry et al. 2017). Information about effectiveness can also be gathered by 
means of meta research, with the help of, for example, systematic reviews, meta-
analyses or network meta-analyses. 
Comparative effectiveness research can be based on register, survey or interview 
data or patient record information or combinations of any of these. The prerequisite 
for comparative effectiveness research on pharmacotherapy is that information on 
clinical outcome variables (such as mortality, incidence rate, clinical health variables) 
and outcome variables reported by patients (e.g. quality of life and health-related 
functioning capacity) is systematically collected to healthcare data resources. 
Comparative effectiveness research also needs data on factors that influence the im-
pact, such as the targeted use of medicinal products and the care process (e.g. dos-
age, duration, treatment adherence, former treatments, follow-up treatments). With 
the help of factors that influence the impact it is possible to define various patient 
groups who benefit from the treatment in different ways. Factors that influence the im-
pact can include age, gender, other medical conditions, the severity of the illness, the 
patient's genotype and the medication currently in use or given earlier. The changes 
in the treatment adherence also influence the impact. When particularly the clinical 
use of new medicinal products is initiated, the factors that influence the impact are not 
very well known, and additional research data is needed on them continuously. 
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Research is needed not only on the effectiveness of pharmacotherapy but also the ef-
fectiveness of other interventions related to pharmacotherapy, such as the effective-
ness of health applications and meters, monitoring of drug therapy and medication as-
sessments, and the effectiveness of the methods used for promoting treatment adher-
ence. 
Research Topics 
• The effectiveness and factors that influence the impact of new medicinal 
products and medicines of significance in terms of cost or number of us-
ers (e.g. biological drug therapies for rheumatoid arthritis, diabetes, and 
haematological, oncological and neurological disorders, medication for 
rare illnesses).  
• The effectiveness of preventive pharmacotherapy, such as drug treat-
ment of high blood pressure, high cholesterol and diabetes. 
• Identifying the patients who will benefit the most from treatments with 
the help of real-world data, biobanks, genetic data and laboratory tests. 
• Methods for measuring the effects of medication. 
• Prevention and forecasting of infections with the help of big data. 
• The development of disease progression models with the help of real-
world data. 
• The experiences of medication users of the benefits and adverse effects 
of medication. 
• The health and financial impacts caused by unfounded drug therapies, 
ineffective pharmacotherapy processes and medication errors. 
3.3.4 Costs and Economic Assessment of Medicinal 
Products and Pharmacotherapy 
1) New and expensive medicinal products 
The increasing pharmaceutical expenditure may derive from the increase in the 
amount of use, price increases or renewing range of medicinal products. International 
factors, such as the European community regulations, trade agreements and the 
availability of medicines, also greatly affect the use and prices of medicines, and re-
search and development of the pharmaceutical industry. 
It is sensible to focus the research on the cost of medicines to medicines which gener-
ate the largest costs due to large amount of use or expensive medicines. New medi-
cations are invariably expensive and, particularly at the initial stages of clinical use, 
they are authorized to a relatively small group of patients. Information on the actual 
effectiveness and safety of medicinal products is gradually complemented after the 
medicinal product has entered the market. 
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On the other hand, the sensible use of generic drugs and biosimilars enables the in-
troduction of new innovative drugs. As part of the implementation programme for ra-
tional pharmacotherapy, we strive to increase the introduction of biosimilars and to 
promote price competition. 
In the coming years, new drug therapies will be even more precisely tailored for each 
patient for improved effectiveness and safety. The decisions on the introduction of 
new medicinal products are usually far-reaching both therapeutically and financially. 
Open questions include such as the impacts of different financing and payment meth-
ods on the availability and arrangement of treatment and the prioritisation of different 
treatments or patient groups. Systematic register-based monitoring and research on 
the use of new and expensive medicinal products is needed, monitoring not only the 
clinical outcome variables but also the treatment outcomes in a wider scale, such as 
in terms of working and functional capacity, or quality of life. 
Research Topics 
• Introduction of new medicines, generic drugs and biosimilars, market 
shares, and other factors affecting the selection of treatments and pa-
tients. 
• Monitoring and management of the budget impact of the use of new me-
dicinal products and how to affect them. 
• The causes of cost increases in various medicinal product groups. 
• Drug and medication costs and the impact of pharmacotherapy on the 
use of other resources. 
2) Economic Evaluation 
Pharmacoeconomics applies the methods of health economics to studying the phe-
nomena related to pharmacotherapy. In economic evaluation, the costs and health ef-
fects of the drug therapy under assessment are compared to one or several alterna-
tive treatments with the same therapeutic indication. The objective is to identify the 
treatments that produce as high health benefits as possible with the resources availa-
ble. This information is needed continuously as background information for treatment-
related decisions. In most cases, the economic assessment is based on cost-effec-
tiveness or cost-utility analysis. 
An economic assessment is typically performed by means of modelling. Modelling is 
used for various reasons, for example, because usually not all data needed for an 
economic assessment has been collected in a single study or because the applicabil-
ity of clinical trials on the Finnish population is limited. The structure of the model and 
the values fed into the model must describe the Finnish target population and 
healthcare system as well as possible. The values refer to, for example, progression 
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of the illness or changes in the state of health, life expectancy, health-related quality 
of life, treatment processes or parameters describing the use of resources. The pro-
duction and publication of such information, using data accumulating into, for exam-
ple, healthcare registers, biobanks, patient information systems or other health and 
social services data resources would support making of modelling-based economic 
assessments in Finland. 
If all information on health benefits, adverse effects, use of healthcare resources and 
healthcare costs relevant with a view to economic assessment were collected into 
health and social services data resources, in certain cases it might be justified to base 
the economic assessment on this data instead of combining data from various 
sources by means of modelling. 
Research Topics 
• Production of cost-effectiveness data to support decision-making on pre-
scriptions. 
• The cost-effectiveness of new medicinal products and medicines of sig-
nificance in terms of cost or number of users.  
• Research supporting economic assessment, and building and parametri-
sation of models. Producing data from, for example, the following: prog-
nosis of a condition, description of the target group for treatment (the 
factors that influence the impact in particular), use of alternative treat-
ments (dosage, duration, treatment adherence), treatment outcomes, 
use of resources. 
• Measuring and detailed characterisation of the health-related quality of 
life. 
• Further development of research methods. 
 
3) The Role of Drug Reimbursement System in Steering Rational Use of Medi-
cines 
Attention should be paid to the functionality of the drug reimbursement system and 
the capacity of the patients to acquire the medication they need. The drug reimburse-
ment system used in Finland is based on the severity of the condition: the share of re-
imbursement rises in proportion to how severe and how long-term illness the patient 
has. Reimbursment eligibility is justified with a specified medical certificate particularly 
in case of illnesses which require expensive medication or cause major expenses. 
This way, medication expenditure is steered towards severe and long-term illnesses. 
In a drug reimbursement system based on the amount of costs only, the prescribing 
practices can be steered by other means. Changes in the Finnish drug reimbursement 
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system may have different repercussions that change the use of medication, on which 
more research data would be needed. 
In Finland, the financial status of the medication user does not affect the drug reim-
bursement paid to him or her. However, the reimbursability of a medicinal product is 
an important requirement for the access to medication. People with low incomes get 
support for their necessary medication acquisitions also from social assistance. In the 
Finnish system, people with low incomes may need to make compromises on their 
medication purchases. This is an essential issue with a view to equal access to phar-
macotherapy, and more information is needed on the impacts of income and financial 
difficulties on the use of medication. 
Research Topics 
• The impacts of changes in the drug reimbursement system, competition 
within the pharmaceutical sector and various medicines policy measures 
on medication expenses. 
• The impacts of changes in the drug reimbursement system on the use of 
medication. 
• Assessment of the coverage and fairness of the drug reimbursement 
system on the background of medicines policy measures. 
• Equality in the availability of and access to medication (e.g. the patient's 
possibilities to acquire the medication he or she needs). 
• The differences in the medicines policies, medication expenses and 
drug reimbursement systems in different countries. 
• The possibilities of the drug reimbursement system to steer the appropri-
ateness of pharmacotherapy. 
• The impacts of multisource financing system of medicines on prescribing 
practices. 
• The extent of support for pharmacotherapy via social assistance. 
• The impacts of the generic substitution system and the reference price 
system on medication expenditure and use of medication. 
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4 Improving the Preconditions of 
Research 
4.1 Enhancing Cooperation between Research 
Groups with the Help of Research 
Networks 
Functional national and international cooperation and networking is the precondition 
of successful and high-quality research operations in the field of rational pharma-
cotherapy as well. Through cooperation research groups strive to enhance their com-
petences and versatility, boost the use of resources targeted for research, and im-
prove the mobility and application of research data. In an ideal situation, rational phar-
macotherapy is based on national and international scientific research produced for 
the needs of health and social services by an active network of researchers. The co-
operation of researchers with the healthcare and social services organisations and 
professionals and medication users is an essential part of the research process. 
There are researchers in various research networks within the health and social ser-
vices sector who conduct research related to rational pharmacotherapy. However, 
there has been no research networks focused specifically on rational pharmacother-
apy in Finland. Such a network is now being assembled as part of the implementation 
programme for rational pharmacotherapy (Ministry of Social Affairs and Health 2017). 
The purpose of the research network is 1) to increase collaboration between re-
searchers by various means, 2) strengthen the methodological competence, 3) in-
crease multidisciplinary research and 4) expand the understanding of pharmacother-
apy as part of the holistic care process and everyday lives of the patients. When plan-
ning and implementing research, account is taken of patient orientation and medica-
tion user orientation. Networks are used for the planning and implementation of re-
search, and practical application of research results. The researchers seek to specifi-
cally develop collaboration with healthcare and social services professionals and pa-
tients in the planning and implementation of research. 
The researchers also aim to strengthen international research cooperation. Here as 
well, they can take advantage of the existing versatile cooperation and networks or 
create new connections. New technologies are used for promoting networking, which 
enables virtual communications and operations (e.g. research meetings and semi-
nars, and researcher training) Researcher and expert visits are also encouraged. The 
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goal is to establish new concrete research projects and increase researcher training 
and potentially research funding applications. 
4.2 Research and Development Aimed at 
Developing the Operations of New Health 
and Social Services Regions 
The strategic goal of research is to bring the academic and practical clinical research 
closer to each other than they are today. Research topics arising from practical needs 
serve well the promotion of rational pharmacotherapy. Research cooperation and joint 
research projects create new practices and new competences both for the academic 
and clinical stakeholders. Cooperation promotes the application of the competence in 
academic methodology and internationally established good practices to supporting 
the local development work. In addition, cooperation enables sharing the results of lo-
cal research and development work with other practitioners and, in the form of publi-
cations, on national and international publication forums. 
State Research Funding (VTR, formerly Special State Subsidy, EVO funding) has en-
abled the development of operations and competences with the help of research and 
training. In the future, it should be ensured that research, development, and training 
continue to be included as a part of the new health and social services system. This 
calls for allocation of resources. Training and research not only develop the local ap-
proaches but also enhance expertise and competence. A lot of R&D is produced 
through specialisation training (e.g. physicians, psychologists, qualified chemists, 
pharmacists, social workers), which should be taken into account in the development 
funding for health and social services. Health and social services regions also need 
infrastructure that supports research and assessment work. 
4.3 Ensuring Research Funding 
One threat to implementation of research related to rational pharmacotherapy is the 
scarcity of resources and research funding. For the most part, research funding has 
been granted on quite short-term basis and to individual researchers. 
The rational pharmacotherapy research described in this research strategy may have 
significant and extensive national impacts on the promotion of medication safety and 
the development of cost-effective drug therapies and medication practices. In spite of 
its significance, no extensive funding schemes have been set up for research within 
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the field. Therefore, in the future we should set it as our goal to have a funding 
scheme set up for research promoting rational pharmacotherapy through, for exam-
ple, the Government's strategic research funding and/or the Academy of Finland. 
Medication is a major expense item in the Finnish health and social services system 
(National Institute for Health and Welfare 2017). The annual direct medication costs 
amount to approximately 3 billion euros and they account for about 12% of the overall 
healthcare expenditure (Finnish Medicines Agency Fimea and Social Insurance Insti-
tution of Finland 2016). This share does not include the resources needed for provi-
sion of pharmacotherapy. The functionality of the provision of pharmacotherapy is of 
decisive importance with a view to the actual overall benefits gained through drug 
treatments in proportion to the overall costs caused by the provision of pharmacother-
apy. 
4.4 Utilisation of New Data Resources 
The Finnish healthcare system has substantial data resources, which could be used 
more for research purposes than is done today. These data resources enable gather-
ing of information about the effectiveness of care. The Government Bill to Parliament 
as a Law on Secure Exploitation of Health and Social Services Data (Government Bill 
159/2017) proposes establishment of a national licensing authority to coordinate 
granting of research permits for the use of personal customer data and other personal 
information related to health and welfare. In the long run, this might make granting of 
access rights and availability of register data significantly easier. 
The objective of the implementation programme for rational pharmacotherapy is that 
the data accumulating in health and social services data resources would be nation-
ally comprehensive, of high quality, in a usable format and readily available for sup-
porting knowledge management (Ministry of Social Affairs and Health 2018a). Health 
and social services data resources refer to the real-world data accumulating in such 
places as healthcare registers, patient information systems and Kanta services, bi-
obanks and genome databases (Ministry of Social Affairs and Health 2018a). 
The data routinely accumulating in health and social services data resources is the 
prerequisite for the implementation of comparative effectiveness research on pharma-
cotherapy. The data can be used for many other purposes as well, including monitor-
ing the implementation of decisions and recommendations related to the use of medi-
cation; enhancing research opportunities; fulfilment of the obligation to produce data 
potentially related to conditional reimbursement decisions; monitoring of the impacts 
and costs of drug therapies; production of regional reference data; study of the use 
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and way of using the treatments available; fulfilment of the obligation to produce data 
related to adaptable licencing and conditional marketing authorisation procedures; 
and complementing the research data of pharmaceutical companies. 
The lack of comprehensive registers on medication purchases and prescriptions has 
been a significant shortcoming from the viewpoint of the assessment of pharma-
cotherapy in outpatient care. The prescription database maintained by Kela only rec-
ords data on outpatient medication purchases reimbursed by Kela; in 2015 the data-
base included 44 million prescriptions on 56 million prescriptions delivered. The entry 
of all electronic prescriptions into the Prescription Centre and Prescription Archive as 
from 1 January 2017 opens new opportunities for prescription register-based re-
search. The information centrally available on medication used in inpatient care only 
includes sales data with wholesale prices. Research on the use and costs of medica-
tions used in hospitals and other care facilities would require centralised data on the 
actual medication expenditure and patient-specific data on the use of medication dur-
ing inpatient care. 
In outpatient care, medication safety information is not collected in a comprehensive 
manner. Hospitals, on the other hand, collect medication safety information in their 
electronic systems in increasing amounts. The future health and social services re-
gions should collect quality and effectiveness data from the perspective of medication 
safety to be used as a basis for further development. The measures that enhance the 
use of data when making care decisions is an important area of development. 
A monitoring system of prescription practices is a precondition for the evaluation of 
the rationality of pharmacotherapy. The sales statistics of medication and Kela statis-
tics enable observation of the consumption and use of medication at a general level. 
In addition, research data is needed on how pharmacotherapy was implemented, 
which potential problems related to prescription practices occurred, how extensive 
these problems were, and which factors contributed to them. Problems can be identi-
fied and verified using information on medication purchases and other register-based 
data at a personal level. However, to ensure the rationality of pharmacotherapy, more 
exact information than is currently available would be needed on the indication for use 
and the duration of use of the drug. The register data is not yet comprehensive in this 
respect. 
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4.5 Utilisation of Indicator Data for Research 
Purposes 
Indicators are used for describing the current state of affairs, monitoring a change in 
time and comparing different areas with each other. Indicator data can be used for the 
purposes of knowledge management, decision-making and steering. Indicator data 
does not replace research data, but it provides information on which phenomena 
should be targeted next in scientific research. Research is needed for examining 
cause and effect relationships and as a foundation for development measures. 
Indicators for monitoring rational pharmacotherapy have been considered as part of 
the implementation programme for rational pharmacotherapy. Indicators would allow, 
for example, monitoring of and reporting on medication expenditure, the development 
of the use and consumption of medication, and the quality and effectiveness of phar-
macotherapy in the national scale, in different areas, such as counties, at a local level 
and by organisation. Different indicators are needed for follow-up and steering of op-
erations at different levels (figure 2). 
Figure 2. The various levels of the need of information on rational pharmacotherapy (Hakoinen et al. 2017) 
The Ministry of Social Affairs and Health and Sitra have started to draw up national 
‘information packs on health and social services’ to be used as a tool for steering the 
organisation of healthcare and social services. Different health and social services 
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have been integrated into entities that make sense from the client's point of view. A 
separate information pack has also been compiled on the pharmaceutical service. The 
objective is that the information packs would also make it easier to compare the qual-
ity and cost of services between different areas than before. The information pack on 
pharmaceutical service was piloted in 2017. 
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5 Summary 
The need for research on rational pharmacotherapy is great. Research data is needed 
both in support of medicines policy decision-making and for the development of the 
quality and practical modes of operation of drug treatment in, for example, healthcare 
and social services organisations, pharmacies and hospital pharmacies. The research 
data also enables development of the training and competence of healthcare and so-
cial services professionals. The research within the topic area is practical and it can 
support, for example, methodological development or, say, implementation of public 
campaigns. 
The field of rational pharmacotherapy research is wide. This research strategy de-
scribes the needs of research supporting rational pharmacotherapy from various dif-
ferent perspectives. The objective was to describe research themes and topics and to 
present them in concrete terms, not to prioritise them in any way. Research related to 
rational pharmacotherapy is conducted all over Finland in many fields of science and 
in different research groups. It is hoped that the research strategy would serve as a 
tool for focusing research and increasing cooperation, and for making new research 
initiatives within this area of research. 
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